IR 820 dye encapsulated in polycaprolactone glycol chitosan: Poloxamer blend nanoparticles for photo immunotherapy for breast cancer

In the present study, we have fabricated biocompatible and biodegradable monodisperse IR 820 encapsulated
polycaprolactone (PCL) glycol chitosan (GC): Poloxamer blend nanoparticles (PP-IR NPs) for imaging and effective
photo-immunotherapy. IR 820 has been used as an imaging and photothermal agentwhereas glycol chitosan
(GC) as an immunostimulatory agent. The combination of IR 820, poloxamer, and GC can be used effectively for
photoimmunotherapy for cancer, drug-resistant and TNF-α resistant estrogen positive breast cancer. PP-IR NPs
are stable in aqueous solution. The uniform size of 100–220 nm with a high zeta value of +38 ± 2 mV led
them to accumulate in cancer cells. Laser treatment did not affect the morphology of PP-IR NPs as observed
under the transmission electron microscope (TEM). In vitro cytotoxicity studies onMCF-7 cells showed enhanced toxicity upon laser treatment. Further, we validated the cell death by reactive oxygen species (ROS) production.Our studies thus showed that PP-IR NPs are effective in suppressing metastatic cancer as the combinational therapy leads to the formation of apoptotic bodies in MCF-7 cells.